Another Drug Shows Potential for Functional Cures in Chronic Hepatitis B

A phase II study found that the investigational siRNA therapy HRS-5635 reduced hepatitis B surface antigen levels in patients with chronic infection. Among participants receiving the highest dose, 19% met the study’s definition of a functional cure 24 weeks after treatment ended. Researchers reported a dose-dependent antiviral response and said the regimens were generally well tolerated. The findings were presented at a liver disease meeting in Denver.